Maze Therapeutics Inc
MAZE14.685USD
-0.215-1.44%
Market hours （ET）Quotes delayed by 15 min
643.16MMarket Cap
LossP/E TTM
More Details of Maze Therapeutics Inc Company
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
Company Info
Ticker SymbolMAZE
Company nameMaze Therapeutics Inc
IPO dateJan 31, 2025
CEODr. Jason V. Coloma, Ph.D.
Number of employees125
Security typeOrdinary Share
Fiscal year-endJan 31
Address171 Oyster Point Boulevard, Suite 300
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94080
Phone16508505070
Websitehttps://www.mazetx.com/
Ticker SymbolMAZE
IPO dateJan 31, 2025
CEODr. Jason V. Coloma, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Dr. Richard H. Scheller, Ph.D.
Dr. Richard H. Scheller, Ph.D.
Independent Director
Independent Director
20.74K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
8.94K
--
Mr. Neil Exter
Mr. Neil Exter
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Chairman of the Board, Co-Founder
Chairman of the Board, Co-Founder
--
--
Dr. Jason V. Coloma, Ph.D.
Dr. Jason V. Coloma, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Alan B. Colowick, M.D.
Mr. Alan B. Colowick, M.D.
Independent Director
Independent Director
--
--
Ms. Jillian Connell
Ms. Jillian Connell
Investor Relations
Investor Relations
--
--
Dr. Jamie Brush, M.D.
Dr. Jamie Brush, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Dr. Richard H. Scheller, Ph.D.
Dr. Richard H. Scheller, Ph.D.
Independent Director
Independent Director
20.74K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
8.94K
--
Mr. Neil Exter
Mr. Neil Exter
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Chairman of the Board, Co-Founder
Chairman of the Board, Co-Founder
--
--
Revenue Breakdown
FY2024
No Data
By RegionUSD
Name
Revenue
Proportion
United States
167.50M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Third Rock Ventures, LLC
16.04%
Frazier Life Sciences Management, L.P.
10.16%
ARCH Venture Partners
9.41%
Deep Track Capital LP
7.46%
Matrix Capital Management Company, LP
5.68%
Other
51.25%
Shareholders
Shareholders
Proportion
Third Rock Ventures, LLC
16.04%
Frazier Life Sciences Management, L.P.
10.16%
ARCH Venture Partners
9.41%
Deep Track Capital LP
7.46%
Matrix Capital Management Company, LP
5.68%
Other
51.25%
Shareholder Types
Shareholders
Proportion
Venture Capital
39.35%
Private Equity
15.77%
Hedge Fund
15.41%
Investment Advisor/Hedge Fund
13.46%
Individual Investor
5.91%
Investment Advisor
5.58%
Endowment Fund
1.46%
Family Office
1.10%
Research Firm
0.11%
Other
1.87%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
99
42.51M
97.06%
+14.68M
2025Q1
93
44.69M
102.04%
+15.27M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Third Rock Ventures, LLC
7.02M
16.04%
--
--
Mar 31, 2025
Frazier Life Sciences Management, L.P.
4.45M
10.16%
+322.34K
+7.81%
Apr 25, 2025
ARCH Venture Partners
4.12M
9.41%
--
--
Mar 31, 2025
Deep Track Capital LP
3.27M
7.46%
+245.64K
+8.12%
Mar 31, 2025
Matrix Capital Management Company, LP
2.49M
5.68%
--
--
Mar 31, 2025
Foresite Capital Management, LLC
2.46M
5.61%
+2.00
+0.00%
Mar 31, 2025
Alphabet, Inc.
2.41M
5.51%
--
--
Mar 31, 2025
Andreessen Horowitz
1.70M
3.89%
+1.70M
--
Mar 31, 2025
Janus Henderson Investors
1.25M
2.85%
+1.25M
--
Mar 31, 2025
General Catalyst Partners
1.04M
2.37%
+1.04M
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.82%
ALPS Medical Breakthroughs ETF
0.36%
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
Schwab U.S. Small-Cap ETF
0%
ProShares Hedge Replication ETF
0%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.82%
ALPS Medical Breakthroughs ETF
Proportion0.36%
iShares Micro-Cap ETF
Proportion0.02%
iShares Russell 2000 Value ETF
Proportion0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
